Thus, it would be safe to say that AMPK is a potential molecular target for cancer therapy employing chemoprevention and chemosensitization approaches, irrespective of its individual pro- or anti-tumorigenic/neoplastic effects. This evidence concerns the gene PRKAA2 and cancer.